Skip to main content

Table 7 Model parameters used in validating the model externally

From: QSAR, molecular docking studies, ligand-based design and pharmacokinetic analysis on Maternal Embryonic Leucine Zipper Kinase (MELK) inhibitors as potential anti-triple-negative breast cancer (MDA-MB-231 cell line) drug compounds

Name

pIC50

AATS6i

ATSC8i

GATS5s

VR1_Dze

C2SP3

YPred

1

5.8697

161.5169

48.7326

0.8808

292.3360

6

5.8575

20

5.8761

162.0662

40.5484

0.8599

336.7858

6

5.8355

25

5.7447

161.1486

43.7089

0.8297

443.9988

6

5.8080

26

5.7235

161.4648

47.3323

0.7449

293.8548

6

5.6361

4

5.8477

161.4031

48.9774

0.8945

288.8093

6

5.8647

41

5.7520

161.6404

55.2788

0.9363

360.7402

6

6.0801

42

5.9914

161.9008

47.3935

0.8602

358.8289

6

5.9095

43

5.9626

162.5176

82.5586

0.8348

356.6440

6

6.3221

48

5.6968

158.9117

24.3199

1.0608

405.1766

6

5.6558

5

5.8761

161.1950

49.3864

0.8916

288.7227

6

5.8413

52

5.5302

158.5990

38.7462

1.0551

405.2722

6

5.7680

53

5.6003

159.3748

13.5155

1.0230

410.7551

6

5.5391

57

5.6478

160.7295

22.3043

1.0283

421.4272

7

5.5005

58

5.1232

161.2564

29.4073

1.0188

398.3031

8

5.3008

6

5.7471

161.839

42.3780

0.8672

288.5304

6

5.8016

60

5.4498

163.1298

37.0344

0.8237

307.2417

7

5.5363

16

5.8794

162.1464

52.3900

0.6452

289.6975

6

5.6169

8

6.4685

161.2731

51.2615

0.8828

536.4764

6

6.0575